How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/agalsidase-beta.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-14 · How we verify

Fabrazyme — Competitive Intelligence Brief

Fabrazyme (AGALSIDASE BETA) competitive landscape: 2 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Hydrolytic Lysosomal Neutral Glycosphingolipid-specific Enzyme [EPC]. Area: Metabolic.

marketed Hydrolytic Lysosomal Neutral Glycosphingolipid-specific Enzyme [EPC] Metabolic Enzyme Live · refreshed every 30 min

Target snapshot

Fabrazyme (AGALSIDASE BETA) — Sanofi. Fabrazyme works by replacing the deficient enzyme alpha-Gal A to break down and remove toxic globotriaosylceramide.

Comparator set (2 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Approval / PDUFA
Fabrazyme TARGET	AGALSIDASE BETA	Sanofi	marketed	Hydrolytic Lysosomal Neutral Glycosphingolipid-specific Enzyme [EPC]	2003-01-01
Elfabrio	PEGUNIGALSIDASE ALFA	Chiesi Farmaceutici S.P.A	marketed	Hydrolytic Lysosomal Neutral Glycosphingolipid-specific Enzyme [EPC]	2023-01-01
ELFABRIO	PEGUNIGALSIDASE ALFA-IWXJ	CHIESI FARMACEUTICI SPA	marketed	Hydrolytic Lysosomal Neutral Glycosphingolipid-specific Enzyme [EPC]

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Hydrolytic Lysosomal Neutral Glycosphingolipid-specific Enzyme [EPC] class)

CHIESI FARMACEUTICI SPA · 1 drug in this class
Chiesi Farmaceutici S.P.A · 1 drug in this class
Sanofi · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Fabrazyme — Competitive Intelligence Brief. https://druglandscape.com/ci/agalsidase-beta. Accessed 2026-05-14.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab